Revvity rises before open after earnings lift its profit outlook
Earnings results
- EPS comparison not verified
Actual: $1.38 (adjusted)
- Revenue comparison not verified
Actual: $0.728899 (reported, billions)
- Guidance
Raised 2026 pro forma adjusted EPS to $5.40–$5.45 from $5.30–$5.40; revenue about $2.86 billion versus $2.83–$2.86 billion. Outlook excludes China IDX.
Earnings and the stock move
Revvity’s November 3 earnings release raised its full-year pro forma adjusted profit-per-share outlook and showed better operating margins in both business segments. Life Sciences delivered stronger sales, while Diagnostics converted a larger share of sales into operating profit despite lower reported revenue. These developments improve the profit outlook, although the guidance excludes a China business whose sale has not yet closed. The shares rose before open following the release.
Q3 2026 ended October 4 earnings recap
Revvity rose 8.8% before open on November 3, 2026, after earnings and a higher profit outlook. Improving research demand and stronger margins supported the report.
- The company raised its 2026 adjusted profit-per-share outlook to $5.4–$5.45 from $5.3–$5.4. This outlook excludes the China diagnostics business it has agreed to sell.
- Third-quarter revenue was $728.9 million, up 4.3% from a year earlier. Excluding the China business, revenue was $709.6 million, up 7.4%.
- Adjusted EPS, or profit per share, was $1.38, compared with $0.56 under GAAP accounting rules. The adjustments include intangible-asset amortization and restructuring costs.
- Life Sciences revenue reached about $380 million, up 11%. Its adjusted operating margin rose to 31.5%, meaning more of each sales dollar remained after operating costs.
- Diagnostics revenue fell to about $349 million, but its adjusted operating margin improved to 29.9% from 25.1%. Better profitability helped offset softer reported sales.
- The China business sale remains subject to approvals and is expected to close by the end of 2027. It is a signed agreement, not a completed sale.
Watch the November 13 Investor Day for the next update on growth and spending. Laboratory budgets, execution of the sale and sharp share-price swings remain risks.
Financials and technicals
Charts through Nov 2, 2026. The session move above may reflect later news.
Technical setup and risks
The November 2 close of $151.6 was below the 20-day average of $156.25 and above the 50-day average of $145.02. The pre-market price used for this comparison was $165.01. Sustained regular-session closes above the recent $163–$169 high area would strengthen the recovery; closes below the recent $150–$153 low area would weaken it. Confirm with volume; these levels are approximate.
AI-assisted research with source and calculation checks. Prices may be delayed. Technical charts use the stated completed session, which can precede the quoted intraday move. Educational information; investing involves risk.